{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:22:19Z","timestamp":1790349739438,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jval.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T07:31:27Z","timestamp":1660375887000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Martijn J.H.G.","family":"Simons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin A.","family":"Uyl-de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Mankor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram L.T.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela A.","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim H.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.07.006_bib1","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"9334","key":"10.1016\/j.jval.2022.07.006_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(02)09832-X","article-title":"A\u00a0rational framework for decision making by the National Institute for Clinical Excellence (NICE)","volume":"360","author":"Claxton","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2022.07.006_bib3","series-title":"Methods for the Economic Evaluation of Health Care Programme","author":"Drummond","year":"2005"},{"issue":"5-6","key":"10.1016\/j.jval.2022.07.006_bib4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molonc.2009.05.001","article-title":"Review on early technology assessments of nanotechnologies in oncology","volume":"3","author":"Ret\u00e8l","year":"2009","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.jval.2022.07.006_bib5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Making"},{"issue":"2","key":"10.1016\/j.jval.2022.07.006_bib6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1523-1739.2003.01491.x","article-title":"Scenario planning: a tool for conservation in an uncertain world","volume":"17","author":"Peterson","year":"2003","journal-title":"Conserv Biol"},{"key":"10.1016\/j.jval.2022.07.006_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/1756-0500-5-442","article-title":"Scenario drafting to anticipate future developments in technology assessment","volume":"5","author":"Ret\u00e8l","year":"2012","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jval.2022.07.006_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2016.05.024","article-title":"Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: an early decision analytic model of multiplex targeted sequencing","volume":"107","author":"Doble","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.07.006_bib9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12885-021-08214-8","article-title":"Whole genome sequencing in oncology: using scenario drafting to explore future developments","volume":"21","author":"van de Ven","year":"2021","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.jval.2022.07.006_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1524-4733.2009.00572.x","article-title":"The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer","volume":"12","author":"Garrison","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.07.006_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1472-6963-10-75","article-title":"Implementation by simulation; strategies for ultrasound screening for hip dysplasia in the Netherlands","volume":"10","author":"Ramwadhdoebe","year":"2010","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.jval.2022.07.006_bib12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1186\/s12885-020-07166-9","article-title":"Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness","volume":"20","author":"Lindenberg","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.jval.2022.07.006_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","article-title":"Value of information analysis for research decisions-an introduction: report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force","volume":"23","author":"Fenwick","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2022.07.006_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jval.2020.01.004","article-title":"Value of information analytical methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force","volume":"23","author":"Rothery","year":"2020","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2022.07.006_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jval.2022.07.006_bib16","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","article-title":"Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology","volume":"4","author":"Marquart","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jval.2022.07.006_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12920-020-00814-w","article-title":"Study protocol: whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE)","volume":"13","author":"Samsom","year":"2020","journal-title":"BMC Med Genomics"},{"issue":"7781","key":"10.1016\/j.jval.2022.07.006_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"issue":"7776","key":"10.1016\/j.jval.2022.07.006_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-019-1600-x","article-title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","volume":"574","author":"van der Velden","year":"2019","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jval.2022.07.006_bib20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","article-title":"Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB,C\/IV non-squamous non-small-cell lung cancer","volume":"39","author":"Simons","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2022.07.006_bib21","author":"Hakkaart-van Roijen"},{"key":"10.1016\/j.jval.2022.07.006_bib23","article-title":"Cost-effectiveness and budget impact model of future developments with whole-genome sequencing for lung cancer patients","author":"Simons","year":"2022","journal-title":"Zenodo"},{"issue":"3","key":"10.1016\/j.jval.2022.07.006_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.jval.2022.07.006_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.19.00002","article-title":"Cost effectiveness of multigene panel sequencing for patients with advanced non-small-cell lung cancer","volume":"3","author":"Steuten","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"4","key":"10.1016\/j.jval.2022.07.006_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.29089","article-title":"Clinical next-generation sequencing in patients with non-small cell lung cancer","volume":"121","author":"Hagemann","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2022.07.006_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.083","article-title":"Validation of whole genome sequencing in routine clinical practice","volume":"31","author":"Monkhorst","year":"2020","journal-title":"Ann Oncol"},{"issue":"suppl 5","key":"10.1016\/j.jval.2022.07.006_bib31","doi-asserted-by":"crossref","first-page":"v575","DOI":"10.1093\/annonc\/mdz257.003","article-title":"WGS implementation in standard cancer diagnostics for every cancer patient (WIDE)","volume":"30","author":"Roepman","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jval.2022.07.006_bib32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2022.07.006_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.lungcan.2019.11.022","article-title":"Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis","volume":"139","author":"Tan","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.jval.2022.07.006_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12910-019-0395-5","article-title":"Umbrella and basket trials in oncology: ethical challenges","volume":"20","author":"Strzebonska","year":"2019","journal-title":"BMC Med Ethics"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:41Z","timestamp":1761096701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522021027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1098301522021027"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.07.006","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness and Budget Impact of Future Developments With Whole-Genome Sequencing for Patients With Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}